{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-092213","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.498909+00:00","generated_at":"2026-05-15T19:18:07.014575+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Acadia Pharmaceuticals appoints Jonathan M. Poole to Board of Directors","bullets":["Poole appointed effective March 3, 2026 as Class II director, term expiring at 2027 annual meeting.","He will serve on the Audit Committee; receives $50k annual cash retainer plus $12.5k for committee role.","Initial equity grant with $200k target fair value (split options/RSUs); prorated annual grant of $95,300.","Future annual equity grants of $400k (half options, half RSUs) with quarterly vesting over one year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-092213","json":"https://secwatch.observer/filing/0001193125-26-092213.json","markdown":"https://secwatch.observer/filing/0001193125-26-092213.md","text":"https://secwatch.observer/filing/0001193125-26-092213.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526092213/0001193125-26-092213-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526092213/acad-20260303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:18:07.014575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}